As millions patients struggled to fill their prescriptions for the new weight loss drugs, many have turned to compounded copies.

Researchers at the University of Copenhagen have identified a new drug target for weight loss that curbs appetite, boosts ...

The weight loss injection tirzepatide helped Melanie Ressa lose weight and overcome food noise, emotional eating, and mental ...

Novo Nordisk (NVO) and Eli Lilly (LLY) manufacture the top three weight loss drugs on the market, but heightened demand is ...

(Bloomberg) -- Obesity pill data released by Viking Therapeutics Inc. and AstraZeneca Plc at a big conference foreshadowed an increasingly competitive landscape for weight-loss therapies ...

Virat Kohli and Rohit Sharma came under fire Monday as India chewed over a 3-0 Test series home defeat to New Zealand, with critics calling the team ageing and low on confidence. The cricket ...

on its weight loss medicine VK2735 indicates that Novo Nordisk (NVO) and Eli Lilly (NYSE:LLY), which currently dominate the obesity drug space, could face competition. VK2735, which is being ...

"Losing 3-0 at home is a tough pill to swallow and it calls for introspection," former skipper Sachin Tendulkar wrote on social media. "Was it lack of preparation, was it poor shot selection or ...

Viking Therapeutics (VKTX) released new clinical trial data on Sunday for its experimental weight-loss drugs, which include a highly anticipated oral pill. The San Diego-based company’s stock ...

Viking Therapeutics stock soared 21% in early trade Monday after the biotech posted data on its oral weight-loss drug showing better-than-expected results from a Phase 1 trial. The study of VK2735 ...

AstraZeneca said its experimental weight loss pill was well tolerated by patients in an early-stage clinical trial. The Anglo-Swedish drugmaker's closely watched weight loss pill, AZD5004 ...

And please do keep in touch. … European Union antitrust regulators will decide by Dec. 6 whether to clear Novo Holdings’ acquisition of contract drug manufacturer Catalent, Reuters writes ...